CLINICAL PHARMACOKINETICS OF IFOSFAMIDE IN COMBINATION WITH N-ACETYLCYSTEINE

被引：6

作者：

BENVENUTO, JA ^{[1
]}

AYELE, W ^{[1
]}

LEGHA, SS ^{[1
]}

RABER, MN ^{[1
]}

NICAISE, C ^{[1
]}

NEWMAN, RA ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB CO,WALLINGFORD,CT 06492

来源：

ANTI-CANCER DRUGS | 1992年 / 3卷 / 01期

关键词：

IFOSFAMIDE; N-ACETYLCYSTEINE; PHARMACOKINETICS;

D O I：

10.1097/00001813-199202000-00004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The pharmacokinetics of ifosfamide were studied in 20 patients with soft tissue and bone sarcomas. Drug was administered as a 30-60 min i.v. infusion at 1.2 or 2.0 mg/m2/day for five consecutive days. Some patients also received 1.5 g/m2 of N-acetylcysteine (NAC) administered 3 times per day during the course of therapy. NAC had no effect on ifosfamide pharmacokinetics. There were significant differences in plasma half-life, area under the concentration-time curve and plasma clearance on day 1 versus day 5 of ifosfamide administration. Myelosuppression and granulocytopenia correlated better with day 1 versus day 5 ifosfamide pharmacokinetics suggesting that the alteration of ifosfamide pharmacology with multiple dosing has a significant effect on drug activity.

引用

页码：19 / 23

页数：5

共 21 条

[1]

ALLEN LM, 1975, CLIN PHARMACOL THER, V17, P492

[2]

ALLEN LM, 1976, CANCER TREAT REP, V60, P451

[3]

BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659

[4]

BRYANT BM, 1980, LANCET, V2, P657

[5] HIGH-DOSE IFOSFAMIDE WITH MESNA UROPROTECTION - A PHASE-I STUDY [J].

ELIAS, AD ;

EDER, JP ;

SHEA, T ;

BEGG, CB ;

FREI, E ;

ANTMAN, KH .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (01) :170-178

[6] PRIMING REDUCES THE BONE-MARROW TOXICITY OF CARBOPLATIN [J].

GORE, ME ;

HILLS, CA ;

SIDDIK, ZH ;

SLOANE, JP ;

WINKLEY, AR ;

SMITH, IE ;

MILLAR, JL .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1987, 23 (01) :75-80

[7]

GOREN MP, 1986, LANCET, V2, P1219

[8]

LEGHA S, 1989, P AM SOC CLIN ONCOL, V8, P322

[9] FRACTIONATED IFOSFAMIDE THERAPY PRODUCES A TIME-DEPENDENT INCREASE IN IFOSFAMIDE METABOLISM [J].

LEWIS, LD ;

FITZGERALD, DL ;

HARPER, PG ;

ROGERS, HJ .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) :725-732

[10] IFOSFAMIDE PHARMACOKINETICS AND NEUROTOXICITY [J].

LEWIS, LD ;

MEANWELL, CA .

LANCET, 1990, 335 (8682) :175-176

← 1 2 3 →